ClinicalTrials.gg
CompletedNCT05961384Updated Aug 15, 2023

Phase 1 Study to Determine the Metabolism and Clearance of Baxdrostat

A Phase 1 interventional study of baxdrostat in Hypertension, sponsored by AstraZeneca. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-15.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2022, 4 years 10 months ago, and no results have been posted to the registry.
  • Registered 1 year 7 months after the study started (first participant enrolled Nov 2021, registered Jul 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing baxdrostat in Hypertension — 2 open to participants now, 4 under way, 3 of them phase 3. baxdrostat · Hypertension.

Enrollment
18th of 18
8 · median 197
Started
2021
with 3 others
Phase 1
7 of 18
none open now
Registered
7th of 18
by date
Lead sponsor
16 of 18
AstraZeneca

Among the 18 studies testing baxdrostat in Hypertension, this one is the 18th largest by enrollment, is one of 4 that started in 2021, is one of 7 in phase 1, and was the 7th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

2 of the 18 studies testing baxdrostat in Hypertension are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About baxdrostat

baxdrostat: first FDA approval 2026 (BAXFENDY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing baxdrostat in Hypertension, or all of them as a file.
02

Study summary

This was a Phase 1, open-label, single dose study in healthy male subjects. The goals of this clinical trial were to determine how baxdrostat might be absorbed and metabolized using radioactive [14C] labeled baxdrostat. Subjects were administered a single oral dose of 10 mg containing approximately 100 μCi of [14C] baxdrostat. Subjects were to be confined to the study site for 9 to 15 days for blood, urine, and feces collections.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • pharmacokinetics (PK)
  • metabolism
  • baxdrostat
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Subjects must meet the following inclusion criteria:

  • Be males of any race between 18 and 55 years of age
  • Have a between 18.0 and 32.0 kg/m2
  • Be in good health, determined by no findings from medical history
  • Have normal renal function, defined as estimated ≥70 mL/min/1.73 m2
  • Agree to use
  • Be able to comprehend and willing to sign an ICF and to abide by the study restrictions
  • Have a history of a minimum of 1 bowel movement per day
  • Agree to refrain from donation of sperm from check-in until 90 days after discharge

Main Exclusion Criteria:

  • Significant history or clinical manifestation of any diseases as determined by the investigator
  • Prolonged (>450 msec)
  • Confirmed (eg, 2 consecutive measurements) systolic BP >140 or \<90 mmHg, diastolic BP >90 or \<50 mmHg, and pulse rate >100 or \<45 beats per minute (bpm).
  • Postural tachycardia (ie, >30 bpm upon standing) or orthostatic hypotension (ie, a fall in systolic BP of ≥20 mmHg or diastolic BP of ≥10 mmHg upon standing).
  • Serum potassium > (5.3 mmol/L; ULN) of the reference range and serum sodium \<lower limit of normal (135 mmol/L) of the reference range
  • , alanine aminotransferase, or total values >1.2 × ULN.
  • A known history of porphyria, myopathy, or active liver disease
  • Use of any prescription medications
  • use (systemic or extensive topical use) within 3 months prior to dosing
  • Subjects who have participated in more than 3 radiolabeled drug studies in the last 12 months
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    10 mg [14C]-bexdrostat

    single oral dose of 10 mg baxdrostat containing 100 μCi of \[14C\] baxdrostat

    Drug: baxdrostat

Interventions

  • a blood pressure lowering drug, oral dose

    Also known as: CIN-107

06

What researchers measure

Primary outcomes

  1. Total radioactivity recovery in urine and feces following administration of [14C] baxdrostat.

    Measurement of total radioactivity recovery in urine and feces to determine the routes, rates of elimination, and mass balance of total radioactivity from \[14C\] baxdrostat.

    Time frame: 1 to 15 days after dosing

  2. Area under the curve [AUC] of baxdrostat and its primary metabolite (CIN-107M) following administration of [14C] baxdrostat to healthy male subjects.

    Area under the curve (AUC)0-∞ and AUC0-last will be determined for baxdrostat and CIN-107M in plasma.

    Time frame: 1 to 15 days after dosing

  3. Cumulative baxdrostat and CIN-107M excreted in urine and fraction of baxdrostat renally excreted following administration of [14C] baxdrostat to healthy subjects.

    Determining cumulative amount of baxdrostat and CIN-107M excreted in urine, clearance of baxdrostat and CIN-107M, and fraction of dose excreted renally (baxdrostat only).

    Time frame: 1 to 15 days after dosing

  4. Maximum concentration [Cmax] for baxdrostat and CIN-107M in plasma.

    Cmax will be determined based on measurement of baxdrostat and CIN-107M in plasma.

    Time frame: 1 to 15 days after dosing

  5. Time to maximum concentration [Tmax] for baxdrostat and CIN-107M in plasma.

    Tmax will be determined based on measurement of baxdrostat and CIN-107M in plasma.

    Time frame: 1 to 15 days after dosing

  6. Terminal elimination half-life (t1/2) for baxdrostat and CIN-107M in plasma.

    t1/2 for baxdrostat and CIN-107M in plasma will be determined based on measurement of baxdrostat and CIN-107M in plasma.

    Time frame: 1 to 15 days after dosing

Secondary outcomes

  1. Quantitative metabolic profiles of baxdrostat in plasma and excreta.

    To determine, where possible, the quantitative metabolite profiles in plasma, urine, and feces after \[14C\]-baxdrostat

    Time frame: 1 to 15 days after dosing

  2. Identification of baxdrostat metabolites in plasma and excreta.

    To determine, where possible, the chemical structure of major metabolites in plasma, urine, and feces after \[14C\]-baxdrostat

    Time frame: 1 to 15 days after dosing

  3. Incidence of treatment emergent adverse events following administration of [14C] baxdrostat.

    Incidence of adverse events will be used to assess the safety and tolerability of \[14C\] baxdrostat when administered to healthy subjects.

    Time frame: 1 to 15 days after dosing

07

Study locations

1 site
  • Labcorp Clinical Research Unit
    Madison, Wisconsin 53704, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Jan 2022, 1 month.

Of 132 industry-sponsored phase 1 interventional studies under Hypertension, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 1 month is below that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 1 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2023
First posted
Jul 27, 2023
StartActual
Nov 18, 2021
Primary completionActual
Jan 15, 2022
CompletionActual
Jan 15, 2022
Last update
Aug 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05961384
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jul 27, 2023
Start date
Nov 18, 2021
Primary completion
Jan 15, 2022
Completion
Jan 15, 2022
Last update
Aug 15, 2023

Study contacts

Nicholas Siebers, MD Siebers, MD
principal investigator · Labcorp Clinical Research Unit, Madison, Wisconsin, USA 53704

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baxdrostat

Start the discussion